Interaction between Atenolol and Diltiazem
Major
Synergy
| ID | DDInter130 and DDInter561 |
| Interaction |
Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers, especially verapamil and diltiazem, are used concomitantly with beta blockers. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. Ventricular asystole, sinus arrest, and heart block have also been reported.
angina
Arrhythmia
arthritis
asthenia
atelectasis
AFIB
carotid artery stenosis
chest pain
pleural pain
constipated
More
|
| Management | Close clinical monitoring of patient hemodynamic response and tolerance is recommended if these agents are used together, and the dosage of one or both agents adjusted as necessary. Patients should be advised to promptly report any symptoms including fatigue, headache, fainting, swelling of the extremities, weight gain, shortness of breath, chest pain, increased or decreased heartbeat, or irregular heartbeat. |
| References | |
| Alternative for Atenolol | - |
| Alternative for Diltiazem |
C05A
Triamcinolone (topical)
Betamethasone (topical)
Triamcinolone (nasal)
Prednisolone (ophthalmic)
Procaine
Tetracaine
Tetracaine (topical)
Zinc sulfate
Hydrocortisone (ophthalmic)
Fluorometholone (ophthalmic)
Dexamethasone (nasal)
More
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.